Dashboard
1
Flat results in Mar 26
- OPERATING PROFIT MARGIN(Q) Lowest at 22.38 %
2
With ROE of 19.26%, it has a attractive valuation with a 1.44 Price to Book Value
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,521 Million (Small Cap)
15.00
NA
2.42%
-0.48
19.26%
1.58
Revenue and Profits:
Net Sales:
170 Million
(Quarterly Results - Jun 2026)
Net Profit:
55 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.49%
0%
20.49%
6 Months
-4.9%
0%
-4.9%
1 Year
-18.02%
0%
-18.02%
2 Years
78.81%
0%
78.81%
3 Years
32.91%
0%
32.91%
4 Years
81.9%
0%
81.9%
5 Years
39.39%
0%
39.39%
Hunan Sundy Science & Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.90%
EBIT Growth (5y)
26.15%
EBIT to Interest (avg)
95.65
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.38
Sales to Capital Employed (avg)
0.68
Tax Ratio
9.36%
Dividend Payout Ratio
43.73%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.87%
ROE (avg)
13.48%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
2.81
EV to EBIT
13.39
EV to EBITDA
12.33
EV to Capital Employed
4.52
EV to Sales
3.30
PEG Ratio
0.69
Dividend Yield
2.38%
ROCE (Latest)
33.73%
ROE (Latest)
19.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
169.90
140.70
20.75%
Operating Profit (PBDIT) excl Other Income
52.30
38.60
35.49%
Interest
0.00
0.00
Exceptional Items
-0.60
1.00
-160.00%
Consolidate Net Profit
54.70
33.80
61.83%
Operating Profit Margin (Excl OI)
279.70%
243.40%
3.63%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 20.75% vs 47.95% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 61.83% vs 43.83% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
652.80
571.80
14.17%
Operating Profit (PBDIT) excl Other Income
208.70
166.20
25.57%
Interest
0.20
0.20
Exceptional Items
4.60
0.40
1,050.00%
Consolidate Net Profit
184.50
144.20
27.95%
Operating Profit Margin (Excl OI)
290.90%
259.60%
3.13%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.17% vs 24.30% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 27.95% vs 163.14% in Dec 2024
About Hunan Sundy Science & Technology Co., Ltd. 
Hunan Sundy Science & Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






